Method for treatment of aneurysms

Abstract

The present invention generally concerns the detection and/or treatment of aneurysm in a non-invasive manner. In particular cases, the invention concerns methods and compositions for localizing a labeled composition to the site of an aneurysm for its detection and, in further cases, treatment of the aneurysm. In specific cases, the composition targets a subendothelial component of the aneurysmal wall, such as a smooth muscle cell exposed at the luminal surface of the vessel. In further specific cases, the composition targets an integrin receptor or laminin.

1 - 45 . (canceled) 
     
     
         46 . A method of treating an aneurysm in an individual, comprising the step of delivering to the individual having or suspected of having a cerebral aneurysm a composition comprising a) a labeled antibody that specifically binds to at least one integrin expressed on contractile SMCs, wherein the labeled antibody localizes to the cerebral aneurysm site, b) a pharmaceutically acceptable excipient, and c) a therapeutic agent, in an amount effective to treat the aneurysm in the individual. 
     
     
         47 . The method of  claim 46 , wherein the individual has an unruptured cerebral aneurysm. 
     
     
         48 . The method of  claim 46 , wherein the individual has a ruptured cerebral aneurysm. 
     
     
         49 . The method of  claim 46 , wherein the therapeutic agent is selected from the group consisting of: a thrombogenic agent, a polymerisable molecule, a protein, a cell growth factor, and a protease inhibitor. 
     
     
         50 . The method of  claim 49 , wherein the therapeutic moiety is selected from the group consisting of: elastin, elastin degradation fragment, fibronectin, fibrinogen, and a cell growth factor. 
     
     
         51 . The method of  claim 49 , wherein the therapeutic agent is a protease inhibitor. 
     
     
         52 . The method of  claim 51 , wherein the protease inhibitor is an elastase inhibitor or a matrix metalloproteinase inhibitor. 
     
     
         53 . The method of  claim 46 , wherein the therapeutic agent comprises a protease inhibitor and fibronectin or fibrinogen. 
     
     
         54 . The method of  claim 46 , wherein the therapeutic moiety comprises fibronectin and a cell growth factor. 
     
     
         55 . The method of  claim 46 , wherein the composition is administered to the individual intravascularly. 
     
     
         56 . The method of  claim 46 , wherein administration of the composition results in accumulation of the labeled antibody and therapeutic agent at the aneurysm wall and thrombosis or aneurism wall thickening. 
     
     
         57 . The method of  claim 46 , wherein the at least one integrin is one or more selected from the group consisting of: α1β1, α7β1, α3β1, and α8β1. 
     
     
         58 . The method of  claim 46 , wherein the composition is delivered in situ via an arterial catheter. 
     
     
         59 . The method of  claim 46 , wherein the labeled antibody is conjugated to an intravascular targeting molecule. 
     
     
         60 . The method of  claim 59 , wherein the intravascular targeting molecule is a polymer. 
     
     
         61 . The method of  claim 60 , wherein the polymer is albumin, transferrin, a globulin, pectin, gelatin, dextran, or a cellulose derivative. 
     
     
         62 . The method of  claim 46 , further comprising administering to the individual a drug or performing surgery or endovascular coiling on the individual.